Clinical Reviews in Allergy & Immunology

, Volume 50, Issue 2, pp 252–272

Biological Modulators in Eosinophilic Diseases

Article

DOI: 10.1007/s12016-014-8444-9

Cite this article as:
Sriaroon, P. & Ballow, M. Clinic Rev Allerg Immunol (2016) 50: 252. doi:10.1007/s12016-014-8444-9

Abstract

Eosinophils can regulate local and systemic inflammation, and their presence in higher numbers appears to play an important role in the pathology of various atopic and inflammatory diseases. Eosinophil maturation, recruitment, and survival depend on several cytokine regulators, including interleukin (IL)-5, IL-4, and IL-13 as well as growth factors such as GM-CSF. Over the last decade, the approach to treating eosinophilic diseases has changed greatly. A number of biologic modulators have been developed to target eosinophilic inflammatory pathways, and their usage has resulted in variable clinical improvement in the treatment of eosinophilic-associated conditions. Novel targeted therapies that are safe and effective for treating these disorders are being investigated. This review summarizes the clinical use of biologic agents that have been studied in clinical trials or approved for treating eosinophilic diseases.

Keywords

EosinophilsEosinophilic diseasesBiologicsMonoclonal antibodiesAsthmaHypereosinophilic syndromeEosinophilic granulomatosis with polyangiitisChurg-Strauss syndromeNasal polyposisEosinophilic esophagitis

Abbreviations

mAb

Monoclonal antibody

HES

Hypereosinophilic syndrome

CHR

Complete hematologic response

CMR

Complete molecular response

CSS

Churg-Strauss syndrome

EGPA

Eosinophilic granulomatosis with polyangiitis

NP

Nasal polyposis

EOE

Eosinophilic esophagitis

CRTH2

Chemoattractant receptor homologous molecule expressed on Th2 cells

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Allergy, Immunology, and Rheumatology, Department of PediatricsUniversity of South FloridaSt. PetersburgUSA